Summary
Beclobrat is a new fibric acid derivative with potent cholesterol- and triglyceride-lowering effects. Pharmacodynamic and pharmacokinetic investigations suggest that once-daily administration in a dosage of 100 mg is admissible. In comparison with other lipid-lowering drugs such a dose, even when calculated on a molar basis, is as effective as 300 mg fenofibrate, 600 mg bezafibrate or 900 mg gemfibrozil. The effectiveness of the drug has been investigated in a variety of studies including patients with hyperlipidemia types IIa, IIb and IV and patients suffering from secondary hyperlipidemia attributable to diabetes mellitus, liver disease, end-stage renal failure requiring hemodialysis, and kidney transplantation. According to the type of hyperlipidemia studied, the mean reduction of LDL-cholesterol ranges from −10% to −28% and that of triglycerides from −20% to −58%. Mean serum HDL-cholesterol increase has been reported to be 8.5–23.9%. In general, side-effects of beclobrate therapy are comparable with those of other fibric acid derivatives, but have to be investigated carefully in a greater number of patients. Advantages in clinical use are administration of a small capsule in a single daily dose. This has been shown to increase patient compliance and is especially useful for treatment of hyperlipidemia in those patients requiring antihyperlipidemic combination therapy or additional medication for further diseases.
Similar content being viewed by others
References
Adrian RW, Ismail S, Jahn U (1983) Pharmacological studies with beclobrate, a new hypolipidemic agent. Arzneimittelforschung 33: 1464–1468
Anwer K, Gabis J, Romstedt K, Gojer C, Akbar H (1985) Beclobrinic acid — a new hypolipidemic agent — inhibits in vitro human platelet activation by blocking prostaglandin synthesis. Life Sci 37: 63–70
Avogaro P, Bittolo Bon G, Gazzolato G, Soldan S (1990) Beclobrate vs bezafibrate in the treatment of type II B hyperlipoproteinemia. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 39–44
Baitsch G, Walter N (1990) Comparative hypolipidemic potency and safety of beclobrate, gemfibrozil, and various forms of diet. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 50–56
Desager JP, Hauglustaine D, Harvengt C (1990) Hemodialysis and the plasma kinetics of beclobrate. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 83–87
Gikalov I, Ifflaender U (1987) Pharmakokinetik und Bioäquivalenz von zwei peroralen Beclobrat-Zubereitungen. Arzneimittelforsch (Drug Res) 37: 1065–1068
Gikalov I, Ifflaender U (1989) Influence of fat content in the food on the absorption of beclobrate (abstract). Eur J Clin Pharmacol [Suppl] 36: A237
Gikalov I, Ziegler WH, Fricker R, Ifflaender U, Meier PJ (1989) Beclobrate — pharmacokinetic studies (abstr). X International Symposium on Drugs Affecting Lipid Metabolism. Houston, Tex, p 99
Goldberg AP, Applebaum-Bowden DM, Biermann EL, Hazzard WR, Haas LA, Sherrad DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkila EA (1979) Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073–1076
Grundy SH, Ahrens EH, Salem G (1972) Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13: 531–551
Huzoor-Akbar CH, Ahn U, Jahn DR, Feller (1982) Effect of beclobrinic acid on human platelet function: mechanism of antiaggregatory action. Clin Res 30:319A
Ifflaender U, Gikalov I (1989) Dose linearity of beclobrate absorption after application of increasing doses (abstr). Eur J Clin Pharmacol [Suppl] 36: A237
Jahn U (1990) Beclobrate: a review of the preclinical examination. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 9–25
Kloer HU, Luley C (1987) Therapie der Hyperlipoproteinämie Typ II und IV. Wirksamkeitsvergleich von Beclobrat und Bezafibrat. Z Allg Med 63: 861–863
Korponay A von, Hasler I (1989) Comparison of the efficacy and tolerance of beclobrate with fibrates (abstr). International Symposium on Drugs Affecting Lipid Metabolism. Houston, Tex, p 130
Korponay A von, Gikalov 1 (1989) The influence of beclobrate on lipid and glucose parameters in diabetic patients (abstr). International Symposium on Drugs Affecting Lipid Metabolism. Houston, Tex, p 130
Kris MT, Dettmer A, Rakette S (1989) Beclobrate: Lt-effect on lipid and glucose metabolism (abstr). Eur J Clin Pharmacol [Suppl] 36: A238
Kris MT, Dettmer A, Rakette S (1990) Long-term efficacy of beclobrate on plasma lipids and blood glucose. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 65–69
Leiss O, Bergmann K von, Gnasso A, Augustin J (1985) Effect of gemfibrozil on biliary lipid metabolism in normolipidemic subjects. Metabolism 34: 74–82
Mordasini R, Merki H, Riesen WF (1990) Beclobrate in the treatment of type II hyperlipoproteinemia; results of different dosages and comparisons with bezafibrate. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 45–49
Mösges R, Adamczyk A, Freitag S (1990) Beclobrate — a new lipoprotein regulator. In: Kostner GM, Sirtori CR (eds). Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Suttgart, pp 31–38
Najemnik C, Lageder H, Regal H, Irsigler K (1981) Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and II b. Arzneimittelforschung 31: 2168–2169
Noseda G, Fragiacomo C, Weibel MA (1989) Beclobrate: a new lipid-lowering drug (abstr). International Symposium on Drugs Affecting Lipid Metabolism, Houston, Tex, p 111
Randinitis EJ, Nelson C, Parker TD III, Kinkel A, Singh S, Welling P (1987) A pharmacokinetic study of a single oral 300-mg gemfibrozil dose in an ephric patients (abstr). Pharm Res 4 [Suppl]: 88
Roth W, Prox A, Ifflaender U (1985) Untersuchungen zur Metabolisierung von Beclobrat bei Ratte und Mensch. Arzneimittelforsch (Drug Res) 35: 244–251
Uglesic A, Nikola L (1986) Beclobrat und Bezafibrat bei Hyperlipidämien vom Typ II und IV. Therapiewoche Schweiz 7: 633–637
Uglesic A (1987) Resultate einer vergleichenden Studie Beclobrat/Bezafibrat und einer Langzeitstudie mit Beclobrat. In: Forster G, Hartmann G (eds) Hyperlipidämien und Beclobrat. Panscientia, Zürich, pp 91–105
Ventura A, Mannarino E, Lupattelli G, Siepi D (1990) Efficacy of beclobrate and gemfibrozil in the treatment of hyperlipoproteinemia. In: Kostner GM, Sirtori CR (eds) Beclobrate, anew lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 57–64
Villanova N, Mazzella G, Minutello A, Roda E (1990) Effects of Beclobrate administration on biliary lipid and steroid metabolism. In: Kostner GM, Sirtori CR (eds) Beclobrate, a new lipoprotein regulator. Hogrefe & Huber, Toronto Stuttgart, pp 70–73
Wanner C, Wieland H, Flügel P, Schollmeyer P, Hörl WH (1989) Pharmacokinetics and therapy of a new fibric acid derivative (Beclobrate) in patients with renal insufficiency (abstr). Eur J Clin Pharmacol [Suppl] 36: A92
Wanner C, Wieland H, Nauck M, Schaeffer G, Schollmeyer P, Hörl WH (1990) Effective hypolipidaemic therapy with beclobrate in hemodialysis patients: interference with carnitine. Nephrol Dial Transplant 5: 588–593
Wille G, Schölmerich J (1989) The influence of liver function on pharmacokinetics of beclobrate in patients with hepatitis and liver cirrhosis (abstr). Eur J Clin Pharmacol [Suppl] 36: A237
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wanner, C., Wieland, H., Schollmeyer, P. et al. Beclobrate: Pharmacodynamic properties and therapeutic use in hyperlipidemia. Eur J Clin Pharmacol 40, S85–S89 (1991). https://doi.org/10.1007/BF01409416
Issue Date:
DOI: https://doi.org/10.1007/BF01409416